title: Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review.
abstract: On the basis of the present studies physical therapy is the most effective basis therapy of peripheral arterial occlusive disease stage II according to Fontaine. The consequent integration of the patients into widespread vascular training groups would be desirable. All present studies with so-called vasoactive drugs led to a statistically significant increase in pain-free walking distance. This is especially true for the substances naftidrofuryl, pentoxifylline, and buflomedil. Nevertheless, these studies do not fully meet the standards set by the GCP or the FDA guidelines. It must also be said that the increase in walking distance by vasoactive substances is less pronounced than the effect obtained by walk training alone. Both the vasoactive therapy and controlled walk training aim at an increase in pain-free walking distance. It is, however, still unclear whether the modes of therapy described influence the primary disease. Angiographically controlled studies are momentarily not available.
authors.affiliation: Medical Clinic, University Hospitals of the Saarland, Homburg-Saar, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Spitzer
authors.forename: R
authors.initials: R
authors.lastname: Bach
authors.forename: H
authors.initials: H
authors.lastname: Schieffer
mesh_terms: D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000534:rehabilitation*; D001537:Bencyclane / Q000627:therapeutic use; D006801:Humans; D009257:Nafronyl / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D016491:Peripheral Vascular Diseases / Q000188:drug therapy* / Q000534:rehabilitation*; D026741:Physical Therapy Modalities; D011759:Pyrrolidines / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*; D016138:Walking
chemical_list: D011759:Pyrrolidines; D014665:Vasodilator Agents; D009257:Nafronyl; D001537:Bencyclane; D010431:Pentoxifylline; C010651:buflomedil